

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Agency for Healthcare Research and Quality****Request for Nominations for AHRQ Study Section Members**

**AGENCY:** Agency for Healthcare Research and Quality (AHRQ), HHS.

**ACTION:** Request for nominations for public members.

**SUMMARY:** In accordance with Title IX of the Public Health Service Act, the authorizing legislation for AHRQ and its grant and contract regulations pertaining to Peer Review of Grant and Contracts 42 CFR Part 67, applications submitted to the AHRQ will be evaluated using the AHRQ peer review process to ensure a fair, equitable, and unbiased evaluation of their scientific and technical merit. The initial peer review of grant applications involves an assessment conducted by panels of experts established to include pertinent scientific disciplines and medical specialty areas. The confidential part of the peer review meetings devoted to critical evaluations will be closed meetings in accordance with section 10(d) of the Federal Advisory Committee Act as amended (5 U.S.C., Appendix 2).

AHRQ is seeking nominations to fill approximately 20 to 30 percent of its study section membership, across the following study sections:

- (1) Health System Research (HSR),
- (2) Health Care Technology and Decision Sciences (HCTDS),
- (3) Health Care Quality and Effectiveness Research (HCQER), and
- (4) Health Care Research Training (HCRT).

The primary research foci and functions of these four study sections are described on the AHRQ Web site (<http://www.ahrq.gov/fund/peerrev/peerdesc.htm>).

Individuals from the health services research and health care community who could serve as peer reviewers in our study sections are sought to replace study section members whose terms have expired. In sending your nomination, please specify the nominee's professional/scientific/technical expertise, affiliations and full contact information, if this information is available.

Factors that will be considered in the selection of individuals to serve on study sections include: competence in a scientific, technical or clinical discipline or research specialty, particularly in health services research,

fairness and evenhandedness in judgment and review, ability to work effectively in a group context, commitment to complete work assignments, adequacy of representations of women, racial and ethnic minority populations, and geographic diversity.

**DATES:** AHRQ would like to receive your recommendations no later than Friday, May 1, 2009.

**ADDRESSES:** Please direct your correspondence to: Kishena C. Wadhwani, PhD., M.P.H., Director, Division of Scientific Review (DSR), Office of Extramural Research, Education and Priority Populations (OEREP), Agency for Healthcare Research and Quality (AHRQ), Department of Health and Human Services (DHHS), 540 Gaither Road, Room 2032, Rockville, MD 20850, Phone: (301) 427-1556, Fax: (301) 427-1562, e-mail: [Kishena.Wadhwani@ahrq.hhs.gov](mailto:Kishena.Wadhwani@ahrq.hhs.gov).

**SUPPLEMENTARY INFORMATION:****Background**

Currently, AHRQ has one chartered Health Services Research Initial Review Group (IRG) responsible for the peer review of research and training grant applications submitted for funding consideration. The IRG is to advise the Director of the Agency on matters related to scientific and technical merit of research grant proposals to improve the quality, safety, efficiency, and effectiveness of health care for all Americans.

This IRG is currently comprised of four subcommittees or study sections, each with a particular research focus around which peer reviewer's expertise is assembled. These study sections convene three times per year to review the grant applications submitted to the three different submission cycles. Study section members are appointed for up to a maximum of four years.

Dated: March 24, 2009.

**Carolyn M. Clancy,**

*AHRQ, Director.*

[FR Doc. E9-7070 Filed 3-31-09; 8:45 am]

**BILLING CODE 4160-90-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Centers for Disease Control and Prevention****Advisory Board on Radiation and Worker Health (ABRWH or Advisory Board), National Institute for Occupational Safety and Health (NIOSH)**

*Notice of Cancellation:* This notice was published in the **Federal Register** on March 19, 2009, Volume 74, Number 5, pages 813-814. The meeting previously scheduled to convene on March 31, 2009 has been cancelled.

*Contact Person for More Information:*

Theodore M. Katz, M.P.A., Executive Secretary, NIOSH, CDC, 1600 Clifton Rd., NE., Mailstop: E-20, Atlanta, GA 30333, Telephone (513) 533-6800, Toll Free 1-800-CDC-INFO, E-mail [ocas@cdc.gov](mailto:ocas@cdc.gov).

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: March 26, 2009.

**Andre Tyler,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E9-7268 Filed 3-31-09; 8:45 am]

**BILLING CODE 4163-18-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****National Cancer Institute; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Initial Review Group; Subcommittee A—Cancer Centers.

*Date:* April 30–May 1, 2009.

*Time:* 8 a.m. to 1 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hilton Washington/Rockville, 1750 Rockville Pike, Rockville, MD 20852.

*Contact Person:* Gail J. Bryant, MD, Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8107, MSC 8328, Bethesda, MD 20892–8328, (301) 402–0801, [gb30t@nih.gov](mailto:gb30t@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: March 26, 2009.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. E9–7308 Filed 3–31–09; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2) notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for the treatment of cancer. The outcome of the evaluation will be a decision whether NCI should support request(s) and make available contract resources for development of the potential therapeutic to improve the treatment of various forms of cancer. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Special Emphasis Panel; Rapid Access to Intervention Development.

*Date:* April 9–10, 2009.

*Time:* 1 p.m.–5 p.m.

*Agenda:* To evaluate the Rapid Access to Intervention Development Portfolio.

*Place:* National Institutes of Health, Executive Plaza North, Conference Room H, 6130 Executive Boulevard, Rockville, MD 20852.

*Contact Person:* Phyllis G. Bryant, Executive Secretary, Program Analyst, Developmental Therapeutics Program, National Cancer Institute, NIH, 6130 Executive Boulevard, Rm. 8022, Bethesda, MD 20892, (301) 496–8720, [pb45q@nih.gov](mailto:pb45q@nih.gov).

This notice is being published less than 15 days prior to the meeting due to scheduling conflicts.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: March 25, 2009.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. E9–7312 Filed 3–31–09; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel, Basic HIV Vaccine Discovery Research (R01).

*Date:* April 29–May 1, 2009.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hilton Silver Spring, 8727 Colesville Road, Silver Spring, MD 20910.

*Contact Person:* Sujata Vihj, PhD, Scientific Review Officer, Scientific Review Program,

Division of Extramural Activities, NIAID/NIH/DHHS, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892–7616, 301–594–0985, [vijhs@niaid.nih.gov](mailto:vijhs@niaid.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: March 26, 2009.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. E9–7304 Filed 3–31–09; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Neurological Disorders and Stroke Special Emphasis Panel, NINDS Conference Grant Review Panel.

*Date:* April 9, 2009.

*Time:* 3 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, 3201, Rockville, MD 20852. (Virtual Meeting).

*Contact Person:* Alan L. Willard, PhD, Scientific Review Administrator, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3208, MSC 9529, Bethesda, MD 20852–9529. (301) 496–5390. [willarda@ninds.nih.gov](mailto:willarda@ninds.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)